Delving into the Latest Updates on Alanylglutamine with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

(D-Glu)-isomer-alanylglutamine, Ala-Gln, Alany Glutamine

+ [14]

Target

IL-17

Mechanism

IL-17 modulators(Interleukin-17 modulators), Amino acid modulators

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseUrogenital Diseases+ [1]

Active Indication

Glutamine Deficiency, CongenitalKidney Failure, ChronicPeritoneal Fibrosis

Inactive Indication

Dietary SupplementPeritonitis

Originator Organization

Fresenius Kabi AG

Active Organization

VUmc

Fresenius SE & Co. KGaA

Zytoprotec GmbH

Inactive Organization

Beijing Suliman Medicine & Technology Co. Ltd.

Academy of Military Medical Sciences

Drug Highest PhaseApproved

First Approval Date

DE (01 Apr 1995)

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC8H15N3O4

InChIKeyHJCMDXDYPOUFDY-WHFBIAKZSA-N

CAS Registry39537-23-0

This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized, or outpatient, persons aged 18 or older. The investigators hypothesis is that alanyl-glutamine supplementation will decrease recurrence and mortality from CDI and these outcomes will be associated with improvement of inflammatory markers and restoration of intestinal microbiota function.

Start Date01 Jun 2021

Sponsor / Collaborator

University of Virginia

[+2]

100 Clinical Results associated with Alanylglutamine

Login to view more data

100 Translational Medicine associated with Alanylglutamine

Login to view more data

100 Patents (Medical) associated with Alanylglutamine

Login to view more data

493

Literatures (Medical) associated with Alanylglutamine

01 Dec 2024·Experimental Eye Research

Hyperglycemia-depleted glutamine contributes to the pathogenesis of diabetic corneal endothelial dysfunction

Article

Author: Yu, Mengmeng ; Wang, Ting ; Chen, Chen ; Xie, Lixin ; Zhou, Qingjun ; Zhao, Can ; Chen, Huilin

Diabetic mellitus (DM) causes various complications, including the corneal endothelial dysfunction that leads to corneal edema and vision loss, especially in the DM patients with intraocular surgeries. However, the pathogenic mechanism of hyperglycemia-caused corneal endothelial dysfunction remains incomplete understood. Here we firstly screened and identified the glutamine contents of aqueous humor (AH) were significantly reduced in the type 2 diabetic patients and type 1 and type 2 diabetic mice. To explore the potential therapeutic effects of glutamine (Gln) supplement on the protection of diabetic corneal endothelial dysfunction, we performed the anterior chamber perfusion with the addition of L-alanyl-L-glutamine (Ala-Gln), and confirmed that Ala-Gln supplement not only accelerated the resolution of corneal edema and recovery of corneal thickness, but also preserved the regular arrangement and barrier-pump function of cornea. Mechanistically, we revealed that the supplements of Ala-Gln protect corneal endothelial cells (CECs) from the deleterious effects of high glucose-induced oxidative stress, mitochondrial dysfunction, and cell apoptosis. Overall, these results indicate the Gln depletion plays an important role in the diabetic corneal endothelial dysfunction, while the Ala-Gln supplement during intraocular surgery provide an effective prevention strategy through regulating the redox homeostasis and mitochondrial function of corneal endothelium.

01 Dec 2024·Poultry Science

Transcriptomic analysis of ileal adaptations and growth responses in growing hens supplemented with alanyl-glutamine dipeptide

Article

Author: Yang, Haiming ; Zheng, Xucheng ; Nazir, Usman ; Yang, Zhi ; Zafar, Muhamamd Hammad ; Wang, Zhiyue ; Fu, Zhenming

The growing phase of laying hens is crucial for growth and development due to its direct impact on their productivity during laying phase. During initial growth phase, intestinal tract undergoes rapid development which requires plenty of nutrients to help laying hens grow and mature. This study investigated the effect of Alanyl-Glutamine (Aln-Gln) levels on growth performance, ileal morphology and transcriptomic analysis of growing Hy-line brown hens. A total of 480 day old Hy-line brown chicks having similar body weight (BW) were randomly divided to be fed diets having 0%, 0.1%, 0.2% and 0.3% Aln-Gln for 6-wks (8 replicates/group, 15 birds/replicate). One bird from every pen was slaughtered and morphological parameters of ileum were evaluated. Results taken on day 42 revealed an improved average daily gain (ADG), final body weight (FBW) and feed-to-gain ratio (F/G) in the birds that consumed 0.2% and 0.3% Aln-Gln supplemented diet (P < 0.05). Ileal morphological assays showed that villus height, villus width and villus to crypts ratio (V/C) were significantly increased at 42 days of age in birds fed diets with 0.2% Aln-Gln (P<0.05). The RNA sequencing (RNA-Seq) was executed to identify differentially expressed genes (DEGs) among groups that found 2265 DEGs (1256 up-regulated; 1009 down-regulated) in ileum tissue. According to the Kyoto Encyclopedia of Genes (KEGG) and Genomic Pathway Enrichment Analysis, majority of DEGs indicated change in metabolic pathways. Genes related to growth factors, intestinal morphology and protein metabolism were up-regulated in test groups as compared to control group. In conclusion, addition of Aln-Gln to the diet improved growth performance and ileum development in growing hens; transcriptomic analysis revealed up-regulation of genes related to growth and intestinal morphology.

01 Nov 2024·International Journal of Biological Macromolecules

Fabrication of versatile and durable superhydrophobic cotton fabrics using PTA-Ala adhesive

Article

Author: Li, Wenji ; Cheng, Jin ; Xing, Tieling ; Chen, Guoqiang ; Yang, Haiwei ; Xing, Lili

In recent years, the preparation of functional textiles based on polyphenols adhesion has received extensive attention and research. However, polyphenols are prone to peroxidation during oxidative polymerization, which can compromise the interfacial adhesion of their monomers. Reintroducing reactive functional groups after oxidative polymerization of polyphenols may potentially compensate for the lost interfacial adhesion while increasing cohesion. In this paper, L-alanine (Ala) is introduced into poly (tannic acid) (PTA) solution to generate the PTA-Ala via Michael addition and Schiff base reaction. Original cotton fabrics are modified with PTA-Ala solution to enhance adhesion strength between the fabrics and subsequent functional modifiers. A silver nanowire network is then incorporated to increase the surface roughness through tannic acid reduction. Finally, polydimethylsiloxane is applied to reduce fabric surface energy, resulting in superhydrophobic multifunctional OH-PDMS/Ag/PTA-Ala/cotton fabrics. The finished cotton fabric exhibits a water contact angle of 166.7 ± 1.9° and a rolling angle of 5 ± 0.5°. Moreover, the fabric features diverse functionalities such as oil-water separation, photothermal conversion, antimicrobial properties, water collection, and anti-icing capabilities, alongside excellent durability and self-healing properties that extend its service life. This finished cotton fabric demonstrates promising applications in oil pollution control, outdoor clothing and medical protection, highlighting its broad across various industries.

100 Deals associated with Alanylglutamine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B05XB02	DB11876

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glutamine Deficiency, Congenital	CN	Fresenius SE & Co. KGaA	03 Apr 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peritonitis	Phase 3	AT	Zytoprotec GmbH	02 Jun 2014
Dietary Supplement	Phase 3	CN	Beijing Suliman Medicine & Technology Co. Ltd.	-
Dietary Supplement	Phase 3	CN	Academy of Military Medical Sciences	-
Kidney Failure, Chronic	Phase 2	AT	Zytoprotec GmbH	16 Mar 2022
Peritoneal Fibrosis	Preclinical	NL	VUmc	03 Nov 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04560309 (CTgov)	Phase 3	Coronary Artery Disease	60	L-alanyl-L-glutamine dipeptide (Glutamine)	zyqnsxzozr(mzebbbdndp) = mivtzhnovf njdfaxrvap (fhlbuvicci, uoionqmfid - bgmifquxlo) View more	-	13 Nov 2023
				Placebo (Control)	zyqnsxzozr(mzebbbdndp) = gufdttrxqw njdfaxrvap (fhlbuvicci, qcoeaicthx - ybivlpxnin) View more
NCT02053350 (CTgov)	Phase 2	Clostridium difficile infection	7	Alanyl-glutamine	vykznjbqxw(vmrouuzsuc) = nqidkympio kbwmxgkwyv (ytdrbniwno, bfmdksjyzs - oynylhsyxb) View more	-	07 Jun 2022
ERA2017	Not Applicable	-	-	ALANYLGLUTAMINE	wegwsznjon(kcnysxhndw) = trrsitkyhd mgylrxqujn (rzatkqmbdw )	-	26 May 2017
				Peritoneal Dialysis Fluid (PDF) + Alanyl-Glutamine (AlaGln)	wegwsznjon(kcnysxhndw) = lkhlsxsvpm mgylrxqujn (rzatkqmbdw )
EUCTR2012-004004-36-AT (ASN2015)	Not Applicable	Peritoneal dialysis-associated peritonitis peritoneal leukocyte immuno-competence \| peritoneal leukocyte transcriptome status	6	Alanyl-Glutamine	focivonazo(hayqmjsvlm) = shtnodqscn fbozeavwfi (gargcfcdrl )	Positive	03 Nov 2015
				AlaGln-supplemented PD fluid	focivonazo(hayqmjsvlm) = jkdkexyfag fbozeavwfi (gargcfcdrl )
NCT00248638 (GLND, CTgov)	Phase 3	Critical Illness	150	15% Clinisol (Glutamine Dipeptide)	vcsbpmyzaq(devmdfaaqc) = ehfdohpzwi koeookysxp (oldixctodg, bdnmpwyrfh - nblowlhdxs) View more	-	13 Feb 2014
				15% Clinisol (Standard)	vcsbpmyzaq(devmdfaaqc) = xhieloyweg koeookysxp (oldixctodg, tifjwbqvqy - okocceeiqz) View more